Wall Street brokerages expect that Biodel Inc. (NASDAQ:ALBO) will report ($0.83) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Biodel’s earnings, with the lowest EPS estimate coming in at ($0.87) and the highest estimate coming in at ($0.79). Biodel reported earnings per share of ($0.90) in the same quarter last year, which would indicate a positive year-over-year growth rate of 7.8%. The business is scheduled to announce its next earnings results on Thursday, August 10th.

On average, analysts expect that Biodel will report full-year earnings of ($3.77) per share for the current financial year, with EPS estimates ranging from ($4.29) to ($3.32). For the next financial year, analysts anticipate that the business will post earnings of ($3.39) per share, with EPS estimates ranging from ($4.03) to ($2.97). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Biodel.

Biodel (NASDAQ:ALBO) last issued its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($1.06) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.04.

Several research firms have issued reports on ALBO. Zacks Investment Research lowered shares of Biodel from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. Needham & Company LLC began coverage on shares of Biodel in a report on Tuesday, July 18th. They issued a “buy” rating and a $35.00 price target on the stock. Finally, Wedbush began coverage on shares of Biodel in a report on Friday, June 30th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Biodel presently has an average rating of “Buy” and an average target price of $31.50.

An institutional investor recently raised its position in Biodel stock. Renaissance Technologies LLC boosted its stake in Biodel Inc. (NASDAQ:ALBO) by 0.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,632 shares of the biopharmaceutical company’s stock after buying an additional 794 shares during the period. Renaissance Technologies LLC’s holdings in Biodel were worth $3,591,000 at the end of the most recent reporting period. 12.35% of the stock is owned by hedge funds and other institutional investors.

Shares of Biodel (NASDAQ ALBO) opened at 22.51 on Friday. The firm’s 50-day moving average price is $23.73 and its 200 day moving average price is $22.09. The stock’s market capitalization is $141.63 million. Biodel has a 52 week low of $10.80 and a 52 week high of $37.69.

TRADEMARK VIOLATION NOTICE: “Brokerages Anticipate Biodel Inc. (NASDAQ:ALBO) Will Post Earnings of -$0.83 Per Share” was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/13/brokerages-anticipate-biodel-inc-nasdaqalbo-will-post-earnings-of-0-83-per-share-3.html.

Biodel Company Profile

Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.

Get a free copy of the Zacks research report on Biodel (ALBO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Biodel (NASDAQ:ALBO)

Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with MarketBeat.com's FREE daily email newsletter.